ClinicalTrials.gg
Not yet recruitingNCT05940116Updated Jul 12, 2023

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of HS-20117 in Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Hansoh BioMedical R&D Company. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
322
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited — 20 open to participants now, 22 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
12th of 26
322 · median 272
Started
2023
with 2 others
Phase 1
11 of 26
10 open now
Primary completion
2025-07
later than 6 of 21 live
Registered
10th of 26
by date

Among the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, this one is the 12th largest by planned enrollment, is one of 3 that started in 2023, is one of 11 in phase 1, reaches primary completion later than 6 of the 21 other live ones, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited are open now, in 4 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.

Read the detailed description

This is a multicenter, open-label, Phase I clinical study of HS-20117 to evaluate the safety, tolerability, PK, immunogenicity and efficacy in participants with advanced solid tumors. The study consists of phase Ia (dose escalation) and phase Ib (dose expansion). The dose-escalation study will be performed to evaluate the safety, tolerability, PK profile, immunogenicity, and efficacy of HS-20117 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The subsequent dose-expansion study will be performed to evaluate the efficacy of HS-20117 in participants with locally advanced or metastatic NSCLC who have progressed after prior platinum-based chemotherapy or are intolerant to platinum-based chemotherapy with EGFR exon 20 insertion mutations, and to explore the efficacy of HS-20117 in participants with other advanced solid tumors.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Solid Tumor

Keywords

  • Non-Small Cell Lung Cancer
  • Solid Tumor
  • HS-20117
  • Epidermal Growth Factor Receptor
  • c-Mesenchymal-Epithelial Transition
  • Bispecific Antibody
  • EGFR exon 20 insertion
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 - 75 years (inclusive).
  2. For the phase Ia study: Participants with locally advanced or NSCLC (stage IIIB/IIIC/IV) with EGFR-activating mutations who have progressed after or are intolerant to or not available to standard of care (SoC).
  3. For the phase Ib study:

    Cohort A: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR exon 20ins mutations who have progressed after prior platinum-based chemotherapy or are intolerant to platinum-based chemotherapy.

    Cohort B: Participants with other advanced solid tumors who have progressed after prior SoC or are intolerant to SoC.

  4. Agree to provide fresh or .
  5. At least one target lesion per the v1.1.
  6. performance status of 0-1.
  7. Minimum > 12 weeks.
  8. Males or Females should be using adequate measures throughout the study.
  9. Females must not be pregnant at screening or have evidence of non-.
  10. Have signed Form.

Exclusion criteria

Exclusion Criteria:

  1. Received or are receiving the following treatments:

    1. For the phase Ib study Cohort A: Previous or current treatment with EGFR exon 20ins targeted therapy.
    2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of HS-20117.
    3. Cytotoxic chemotherapies, drugs or other systematic anti-tumor therapies within 3 weeks prior to the first dose of HS-20117.
    4. Antibodies within 4 weeks prior to the first dose of HS-20117.
    5. Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117.
    6. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.
    7. Major surgery within 4 weeks prior to the first dose of HS-20117.
  2. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
  3. History of other primary .
  4. Untreated, or active central nervous system .
  5. Inadequate bone marrow reserve or organ functions.
  6. Severe, uncontrolled or active cardiovascular disorders.
  7. Severe or uncontrolled systemic diseases.
  8. Severe bleeding symptoms or bleeding tendencies within 1 month prior to the first dose of HS-20117.
  9. Severe arteriovenous thrombosis occurred within 3 months prior to the first dose of HS-20117
  10. Serious infection within 4 weeks prior to the first dose of HS-20117.
  11. Active infectious diseases.
  12. Interstitial lung disease (ILD).
  13. Serious neurological or mental disorders.
  14. History of to any component of HS-20117 or similar drugs.
  15. Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
322 participants (estimated)

Study arms

  • Experimental
    HS-20117

    Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)

    Drug: HS-20117

Interventions

  • Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined. Phase Ib: patients will receive HS-20117 at MED or MAD

    Also known as: PM1080

06

What researchers measure

Primary outcomes

  1. [Phase 1a] Maximum tolerated dose (MTD) of HS-20117

    MTD is defined as the previous dose level at which 2 or more out of 2-6 subjects experienced a DLT.

    Time frame: Cycle 1 (28 days)

  2. [Phase 1a] Maximum applicable dose (MAD) of HS-20117

    MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.

    Time frame: Cycle 1 (28 days)

  3. [Phase 1b] Efficacy of HS-20117: Objective response rate (ORR)

    ORR is defined as the percentage of participants with BOR of confirmed CR or confirmed PR per RECIST v1.1

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

Secondary outcomes

  1. [phase 1a and 1b] Incidence and severity of treatment-emergent adverse events

    Adverse event (assessed according to NCI CTCAE v5.0) is defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: From the date of first dose until 90 days after the final dose. A cycle is 28 days

  2. [phase 1a and 1b] PK parameters: Maximum serum concentration (Cmax) of HS-20117

    The Cmax is the maximum observed serum concentration of HS-20117.

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  3. [phase 1a and 1b] PK parameters: Trough serum concentration (Ctrough) of HS-20117

    Ctrough is the observed serum concentration immediately prior to the next administration.

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  4. [phase 1a and 1b] PK parameters: Time to reach maximum observed serum concentration (Tmax) of HS-20117

    The Tmax is defined as time to reach maximum observed serum concentration of HS-20117.

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days

  5. [phase 1a] PK parameters: Area under the curve from time Zero to end of dosing interval (AUCtau) of HS-20117

    The AUCtau is defined as the area under the serum concentration-time curve during a dose interval time period (tau).

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  6. [phase 1a] PK parameters: Terminal elimination half-life (t1/2) of HS-20117

    The t1/2 is defined as the time it takes for the concentration levels to fall to 50% of their value.

    Time frame: From the date of first dose until 30 days after the final dose. A cycle is 28 days.

  7. [phase 1a] Efficacy of HS-20117: ORR

    ORR is defined as the percentage of participants with BOR of confirmed CR or confirmed PR per RECIST v1.1.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years.

  8. [phase 1a and 1b] Efficacy of HS-20117: disease control rate (DCR)

    DCR is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks) per RECIST v1.1.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years.

  9. [phase 1a and 1b] Efficacy of HS-20117: duration of response (DoR)

    DoR only applies to participants whose best overall response is CR or PR based on assessment per RECIST v1.1. The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying disease.

    Time frame: From the date of CR, PR until the date of disease progression or death, approximately 2 years.

  10. [phase 1a and 1b] Efficacy of HS-20117: progression free survival (PFS)

    PFS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. PFS will be assessed per RECIST v1.1.

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or death, approximately 2 years.

  11. [phase 1b] Efficacy of HS-20117: overall survival (OS)

    OS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of death due to any cause. For each participant who is not known to have died as of the cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 4 years

  12. [phase 1a and 1b] Immunogenicity of HS-20117

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Cycle 1 Day 1: predose through EOT or follow up period (90 days after the last dose).

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Jul 2025, 24 months later.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 11, 2023
StartEst.
Jul 20, 2023
Primary completionEst.
Jul 30, 2025
CompletionEst.
Jul 30, 2027
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05940116
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Jul 20, 2023 (estimated)
Primary completion
Jul 30, 2025 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jul 12, 2023

Study contacts

Peng Zhou
Contact
zhoup7@hspharm.com
+86 18013002767
Dingzhi Huang
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20117

Start the discussion